Redemplo plozasiran Updated Aug 2
The main re-rating event for ARWR is the Phase 3 severe-hypertriglyceridemia (SHTG) topline readout, expected around mid-September 2026 per trial estimates, SHTG is a far bigger market than the ultra-rare FCS indication Redemplo was approved for. Also watch the Aug 4, 2026 earnings call for the first real Redemplo launch revenue commentary, the pending EU decision after the April 2026 CHMP opinion, and direct competition from Ionis' olezarsen (which had its own FDA decision date for SHTG on June 30, 2026).
- FDA-approved commercial product: FDA approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with FCS (NDA; approval press-release 8-K filed Nov 25, 2025), and stored catalyst-outcome data shows ARWR +30.4% on the 1-day move ($44.26 → $57.71) around that catalyst.
- Breakthrough Therapy designation for severe hypertriglyceridemia (TG ≥500 mg/dL) granted Feb 5, 2026, pointing to an accelerated path into a much larger market than FCS.
- Two pivotal Phase 3 SHTG trials (n=446 and n=311) are active/not-recruiting with estimated completion Sept 2026, the big near-term re-rating catalyst.
- FCS is an ultra-rare disease, so the approved indication alone is a small revenue base; Q3 2026 revenue is only estimated at ~$55.4M and the commercial ramp is unproven.
- Binary readout risk: the SHTG Phase 3 topline results are the main driver of the next leg, and a miss would hit the stock hard.
- Direct competition: Ionis' olezarsen had its own FDA decision date for severe hypertriglyceridemia under Priority Review on June 30, 2026 (per stored PDUFA catalyst data), a head-to-head rival in the expansion indication.